EGFR and non-small cell lung carcinoma: The Flatiron Health Database of the U.S. Cancer Electronic Health Record in February 2020 (60) indicated that patients with EGFR ex20ins mutation-positive NSCLC, platinum-based chemotherapy regimens are the most commonly used first-line treatment.